RxDoctor Payments Data

Yue Guo, MD

Internal Medicine · Detroit, MINPI 1841368388

Payments from drug & device makers

$4,055in general payments, 2019–2025

Across 18 payments — averaging $225.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • Sobi, Inc$200
  • Advanced Accelerator Applications$126
  • Takeda Pharmaceuticals U.S.A., Inc.$109
  • Exelixis Inc.$66
  • GSK$53
  • plus $116 from 4 others

What the payments were for

  • Consulting fees$3,09876%
  • Travel & lodging$44811%
  • Food & beverage$51013%

General payments by program year

19
20
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,055 in reported general payments places this provider in the 85th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$56,005
Medicare patients
164
Services billed
509

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide82$1,365,982
ImbruvicaIbrutinib33$1,061,400
CalquenceAcalabrutinib Maleate26$382,307
PomalystPomalidomide17$374,223
VenclextaVenetoclax26$268,354
Imatinib Mesylate74$121,855
Hydroxyurea82$2,230
Dexamethasone56$969
Acyclovir42$319
Potassium Chloride30$301
Prochlorperazine Maleate13$284
Gabapentin21$272
Allopurinol29$243
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen29$208
Ondansetron OdtOndansetron13$173

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$43$1,365,98282 claims
AstraZenecaCalquence$3,386$382,30726 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Detroit

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →